Inhibitor of release of dopamine induced by methamphetamine.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 245.75. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.07 mL||20.35 mL||40.69 mL|
|5 mM||0.81 mL||4.07 mL||8.14 mL|
|10 mM||0.41 mL||2.03 mL||4.07 mL|
|50 mM||0.08 mL||0.41 mL||0.81 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Tateyama et al (1993) 4-Phenyltetrahydroisoquinoline, but not nomifensine or cocaine, inhibits methamphetamine-induced dopamine release. Eur.J.Pharmacol. 240 51 PMID: 8405121
If you know of a relevant reference for 4-Phenyl-1,2,3,4-tetrahydroisoquinoline hydrochloride, please let us know.
View Related Products by Product Action
Keywords: DA release inhibitors inhibits Dopaminergic Dopamine Receptors Dopaminergic-Related
Citations for 4-Phenyl-1,2,3,4-tetrahydroisoquinoline hydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for 4-Phenyl-1,2,3,4-tetrahydroisoquinoline hydrochloride. Do you know of a great paper that uses 4-Phenyl-1,2,3,4-tetrahydroisoquinoline hydrochloride from Tocris? If so please let us know.
Literature in this Area
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.